Trial Profile
A randomized comparison of clinical outcomes between everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in long coronary lesions
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Jun 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary arteriosclerosis; Coronary artery disease; Ischaemic heart disorders
- Focus Adverse reactions
- Acronyms bvs long
- 15 Mar 2020 Status changed from recruiting to discontinued as per results published in the American Journal of Cardiology.
- 15 Mar 2020 Results published in the American Journal of Cardiology
- 17 May 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.